These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26338964)

  • 1. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
    Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
    Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
    Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
    Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
    Nakae S; Sasaki H; Hayashi S; Hattori N; Kumon M; Nishiyama Y; Adachi K; Nagahisa S; Hayashi T; Inamasu J; Abe M; Hasegawa M; Hirose Y
    PLoS One; 2015; 10(11):e0142750. PubMed ID: 26558387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
    Gupta R; Webb-Myers R; Flanagan S; Buckland ME
    J Clin Pathol; 2011 Oct; 64(10):835-44. PubMed ID: 21752797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
    Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
    PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.